Literature DB >> 21377288

Estimation of α/β for late rectal toxicity based on RTOG 94-06.

Susan L Tucker1, Howard D Thames, Jeff M Michalski, Walter R Bosch, Radhe Mohan, Kathryn Winter, James D Cox, James A Purdy, Lei Dong.   

Abstract

PURPOSE: To estimate α/β, the parameter ratio from the linear-quadratic (LQ) model, for Grade ≥2 late rectal toxicity among patients treated on Radiation Therapy Oncology Group (RTOG) protocol 94-06; and to determine whether correcting the rectal dose-volume histogram (DVH) for differences in dose per fraction, based on the LQ model, significantly improves the fit to these data of the Lyman-Kutcher-Burman (LKB) normal-tissue complication probability (NTCP) model. METHODS AND MATERIALS: The generalized LKB model was fitted to the Grade ≥2 late rectal toxicity data in two ways: by using DVHs representing physical dose to rectum, and by using a modified approach in which dose bins in the rectal DVH were corrected for differences in dose per fraction using the LQ model, with α/β estimated as an additional unknown parameter. The analysis included only patients treated with the same treatment plan throughout radiotherapy, so that the dose per fraction to each voxel of rectum could be determined from the DVH. The likelihood ratio test was used to assess whether the fit of the LQ-corrected model was significantly better than the fit of the LKB model based on physical doses to rectum.
RESULTS: The analysis included 509 of the 1,084 patients enrolled on RTOG 94-06. The estimate of α/β from the LQ-corrected LKB model was 4.8 Gy, with 68% confidence interval 0.6 Gy to 46 Gy. The fit was not significantly different from the fit of the LKB model based on physical dose to rectum (p = 0.236).
CONCLUSIONS: The estimated fractionation sensitivity for Grade ≥2 late rectal toxicity is consistent with values of α/β for rectum found previously in human beings and in rodents. However, the confidence interval is large, and there is no evidence that LQ correction of the rectal DVH significantly changes the fit or predictions of the LKB model for this endpoint.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21377288      PMCID: PMC3163802          DOI: 10.1016/j.ijrobp.2010.11.080

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  36 in total

1.  Clinically relevant optimization of 3-D conformal treatments.

Authors:  R Mohan; G S Mageras; B Baldwin; L J Brewster; G J Kutcher; S Leibel; C M Burman; C C Ling; Z Fuks
Journal:  Med Phys       Date:  1992 Jul-Aug       Impact factor: 4.071

2.  Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.

Authors:  M Roach
Journal:  J Urol       Date:  1993-12       Impact factor: 7.450

3.  Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method.

Authors:  G J Kutcher; C Burman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-06       Impact factor: 7.038

4.  Complication probability as assessed from dose-volume histograms.

Authors:  J T Lyman
Journal:  Radiat Res Suppl       Date:  1985

5.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

Authors:  J D Cox; J Stetz; T F Pajak
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

6.  The response of Chinese hamster V79 cells to low radiation doses: evidence of enhanced sensitivity of the whole cell population.

Authors:  B Marples; M C Joiner
Journal:  Radiat Res       Date:  1993-01       Impact factor: 2.841

7.  The effect of cis-diamminedichloroplatinum(II) on radiation damage in mouse rectum after fractionated irradiation.

Authors:  L Dewit; Y Oussoren; H Bartelink; H D Thames
Journal:  Radiother Oncol       Date:  1989-10       Impact factor: 6.280

8.  Chronic radiation damage in the rat rectum: an analysis of the influences of fractionation, time and volume.

Authors:  B M Dubray; H D Thames
Journal:  Radiother Oncol       Date:  1994-10       Impact factor: 6.280

9.  Chronic radiation damage in the rectum of the rat after protracted fractionated irradiation.

Authors:  N Breiter; K R Trott
Journal:  Radiother Oncol       Date:  1986-10       Impact factor: 6.280

10.  Early and late injuries in mouse rectum after fractionated X-ray and neutron irradiation.

Authors:  A Gasinska; B Dubray; S A Hill; J Denekamp; H D Thames; J F Fowler
Journal:  Radiother Oncol       Date:  1993-03       Impact factor: 6.280

View more
  22 in total

1.  Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.

Authors:  Scott C Morgan; Karen Hoffman; D Andrew Loblaw; Mark K Buyyounouski; Caroline Patton; Daniel Barocas; Soren Bentzen; Michael Chang; Jason Efstathiou; Patrick Greany; Per Halvorsen; Bridget F Koontz; Colleen Lawton; C Marc Leyrer; Daniel Lin; Michael Ray; Howard Sandler
Journal:  J Clin Oncol       Date:  2018-10-11       Impact factor: 44.544

2.  The 5-year outcomes of moderately hypofractionated radiotherapy (66 Gy in 22 fractions, 3 fractions per week) for localized prostate cancer: a retrospective study.

Authors:  Yaichiro Hashimoto; Atsushi Motegi; Tetsuo Akimoto; Norio Mitsuhashi; Junpei Iizuka; Kazunari Tanabe; Yuka Ishii; Sawa Kono; Sachiko Izumi; Kumiko Karasawa
Journal:  Int J Clin Oncol       Date:  2017-07-31       Impact factor: 3.402

3.  Image-guided hypofractionated proton beam therapy for low-risk prostate cancer: Analysis of quality of life and toxicity, PCG GU 002.

Authors:  Carlos Enrique Vargas; William Fred Hartsell; Megan Dunn; Sameer Ramchandra Keole; Lucius Doh; John Chang; Gary Lynn Larson
Journal:  Rep Pract Oncol Radiother       Date:  2016-03-04

4.  Use of fractional dose-volume histograms to model risk of acute rectal toxicity among patients treated on RTOG 94-06.

Authors:  Susan L Tucker; Jeff M Michalski; Walter R Bosch; Radhe Mohan; Lei Dong; Kathryn Winter; James A Purdy; James D Cox
Journal:  Radiother Oncol       Date:  2012-06-05       Impact factor: 6.280

5.  Radiobiological analysis of preliminary results of a phase II study of pelvic hypofractionated and accelerated radiotherapy for high-risk prostate cancer patients.

Authors:  Christos Nanos; Vasilios Souftas; Athanasios Zissimopoulos; Michael I Koukourakis
Journal:  Radiat Oncol J       Date:  2022-06-20

6.  Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.

Authors:  Alan Pollack; Gail Walker; Eric M Horwitz; Robert Price; Steven Feigenberg; Andre A Konski; Radka Stoyanova; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; Charlie Ma; Mark K Buyyounouski
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

7.  Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial.

Authors:  Douglas H Brand; Sarah C Brüningk; Anna Wilkins; Katie Fernandez; Olivia Naismith; Annie Gao; Isabel Syndikus; David P Dearnaley; Alison C Tree; Nicholas van As; Emma Hall; Sarah Gulliford
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-01-04       Impact factor: 7.038

Review 8.  The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer.

Authors:  Yasuo Yoshioka; Ken Yoshida; Hideya Yamazaki; Norio Nonomura; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2013-03-29       Impact factor: 2.724

9.  Prospective evaluation of a hydrogel spacer for rectal separation in dose-escalated intensity-modulated radiotherapy for clinically localized prostate cancer.

Authors:  Franziska Eckert; Saladin Alloussi; Frank Paulsen; Michael Bamberg; Daniel Zips; Patrick Spillner; Cihan Gani; Ulrich Kramer; Daniela Thorwarth; David Schilling; Arndt-Christian Müller
Journal:  BMC Cancer       Date:  2013-01-22       Impact factor: 4.430

Review 10.  The potential of mesenchymal stem cells in the management of radiation enteropathy.

Authors:  P-Y Chang; Y-Q Qu; J Wang; L-H Dong
Journal:  Cell Death Dis       Date:  2015-08-06       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.